Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report
Jonathan de Fallois, Sebastian Baatz, Bastian M. Krüger, Lisa-M. Dilz, Andreas Boldt, Julia Beck, Kirsten Bornemann-Kolatzki, Friederike Petzold, Christoph Daniel, Kerstin Amann, Jan Kowald · 2026
Read Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report by Jonathan de Fallois, Sebastian Baatz, Bastian M. Krüger, Lisa-M. Dilz, Andreas Boldt, Julia Beck, Kirsten Bornemann-Kolatzki, Friederike Petzold, Christoph Daniel, Kerstin Amann, Jan Kowald (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13461800.txt.
Description
de Fallois and colleagues reported in 2026 a kidney transplant case where rejection resisted the newest antibody treatment. Antibody-mediated rejection happens when the recipient's immune system attacks the donated kidney. A CD38 antibody drug had worked for six months, yet biopsy still showed inflammation in the graft's small vessels. Blood tests kept finding a pool of memory B cells that lack CD38, the drug's target.
de Fallois added a second antibody aimed at CD20, using a type-II engineered version built for deep B cell depletion. A follow-up biopsy showed the vessel inflammation had resolved. A blood marker of graft injury, donor-derived cell-free DNA, also normalised, matching remission of the rejection. The authors argue resistant cases may be driven by cell pools the first drug cannot reach, and they back tailored, combined B cell strategies for selected patients.
Catalog record
| CREATOR | Jonathan de Fallois, Sebastian Baatz, Bastian M. Krüger, Lisa-M. Dilz, Andreas Boldt, Julia Beck, Kirsten Bornemann-Kolatzki, Friederike Petzold, Christoph Daniel, Kerstin Amann, Jan Kowald |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |